FSHR抗体;FSHR Antibody—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using FSHR mouse mAb (green) and negative control (red).    

  
  

Follicle-stimulating hormone receptor (FSHR) antibodies are biomolecules targeting FSHR, a G protein-coupled receptor critical in reproductive physiology. Expressed primarily in ovarian granulosa cells and testicular Sertoli cells, FSHR regulates folliculogenesis in females and spermatogenesis in males. Anti-FSHR antibodies can be either agonistic or antagonistic, modulating receptor activity. Naturally occurring autoantibodies against FSHR are rare but linked to infertility, ovarian resistance syndromes, or autoimmune disorders.

Research focuses on engineered FSHR antibodies for therapeutic applications. Monoclonal antibodies (mAbs) blocking FSHR signaling are explored in contraception and oncology, particularly cancers expressing FSHR (e.g., ovarian, prostate). Conversely, agonistic antibodies mimicking FSH action may assist in vitro fertilization by enhancing follicular development. Challenges include ensuring antibody specificity due to FSHR's structural homology with other glycoprotein hormone receptors. Recent advances utilize recombinant FSHR extracellular domains or cell-based immunization to generate high-affinity antibodies. Clinical trials remain limited, but preclinical studies highlight their potential in targeting FSHR-overexpressing tumors while sparing normal tissues. Ethical and safety concerns persist, particularly regarding off-target effects on reproductive tissues. Ongoing studies aim to optimize antibody design for precision therapeutics in reproductive health and oncology.